418 related articles for article (PubMed ID: 16785532)
1. The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20.
Teeling JL; Mackus WJ; Wiegman LJ; van den Brakel JH; Beers SA; French RR; van Meerten T; Ebeling S; Vink T; Slootstra JW; Parren PW; Glennie MJ; van de Winkel JG
J Immunol; 2006 Jul; 177(1):362-71. PubMed ID: 16785532
[TBL] [Abstract][Full Text] [Related]
2. Alanine-170 and proline-172 are critical determinants for extracellular CD20 epitopes; heterogeneity in the fine specificity of CD20 monoclonal antibodies is defined by additional requirements imposed by both amino acid sequence and quaternary structure.
Polyak MJ; Deans JP
Blood; 2002 May; 99(9):3256-62. PubMed ID: 11964291
[TBL] [Abstract][Full Text] [Related]
3. Type I CD20 Antibodies Recruit the B Cell Receptor for Complement-Dependent Lysis of Malignant B Cells.
Engelberts PJ; Voorhorst M; Schuurman J; van Meerten T; Bakker JM; Vink T; Mackus WJ; Breij EC; Derer S; Valerius T; van de Winkel JG; Parren PW; Beurskens FJ
J Immunol; 2016 Dec; 197(12):4829-4837. PubMed ID: 27807190
[TBL] [Abstract][Full Text] [Related]
4. Two structurally different rituximab-specific CD20 mimotope peptides reveal that rituximab recognizes two different CD20-associated epitopes.
Perosa F; Favoino E; Vicenti C; Guarnera A; Racanelli V; De Pinto V; Dammacco F
J Immunol; 2009 Jan; 182(1):416-23. PubMed ID: 19109173
[TBL] [Abstract][Full Text] [Related]
5. Mapping of binding epitopes of a human decay-accelerating factor monoclonal antibody capable of enhancing rituximab-mediated complement-dependent cytotoxicity.
Guo B; Ma ZW; Li H; Xu GL; Zheng P; Zhu B; Wu YZ; Zou Q
Clin Immunol; 2008 Aug; 128(2):155-63. PubMed ID: 18502181
[TBL] [Abstract][Full Text] [Related]
6. Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas.
Teeling JL; French RR; Cragg MS; van den Brakel J; Pluyter M; Huang H; Chan C; Parren PW; Hack CE; Dechant M; Valerius T; van de Winkel JG; Glennie MJ
Blood; 2004 Sep; 104(6):1793-800. PubMed ID: 15172969
[TBL] [Abstract][Full Text] [Related]
7. Epitope interactions of monoclonal antibodies targeting CD20 and their relationship to functional properties.
Klein C; Lammens A; Schäfer W; Georges G; Schwaiger M; Mössner E; Hopfner KP; Umaña P; Niederfellner G
MAbs; 2013; 5(1):22-33. PubMed ID: 23211638
[TBL] [Abstract][Full Text] [Related]
8. Binding of submaximal C1q promotes complement-dependent cytotoxicity (CDC) of B cells opsonized with anti-CD20 mAbs ofatumumab (OFA) or rituximab (RTX): considerably higher levels of CDC are induced by OFA than by RTX.
Pawluczkowycz AW; Beurskens FJ; Beum PV; Lindorfer MA; van de Winkel JG; Parren PW; Taylor RP
J Immunol; 2009 Jul; 183(1):749-58. PubMed ID: 19535640
[TBL] [Abstract][Full Text] [Related]
9. A monoclonal antibody against hinge-cleaved IgG restores effector function to proteolytically-inactivated IgGs in vitro and in vivo.
Brezski RJ; Kinder M; Grugan KD; Soring KL; Carton J; Greenplate AR; Petley T; Capaldi D; Brosnan K; Emmell E; Watson S; Jordan RE
MAbs; 2014; 6(5):1265-73. PubMed ID: 25517311
[TBL] [Abstract][Full Text] [Related]
10. New insights in Type I and II CD20 antibody mechanisms-of-action with a panel of novel CD20 antibodies.
Meyer S; Evers M; Jansen JHM; Buijs J; Broek B; Reitsma SE; Moerer P; Amini M; Kretschmer A; Ten Broeke T; den Hartog MT; Rijke M; Klein C; Valerius T; Boross P; Leusen JHW
Br J Haematol; 2018 Mar; 180(6):808-820. PubMed ID: 29468712
[TBL] [Abstract][Full Text] [Related]
11. Novel humanized anti-CD20 antibody BM-ca binds to a unique epitope and exerts stronger cellular activity than others.
Kobayashi H; Matsunaga Y; Uchiyama Y; Nagura K; Komatsu Y
Cancer Med; 2013 Apr; 2(2):130-43. PubMed ID: 23634281
[TBL] [Abstract][Full Text] [Related]
12. Optimization of anti-CD20 humanized antibody hu8E4 by site-directed mutation based on epitope analysis.
Chen Y; Chen L; Lu Q; Meng Y; Wang C; Wang L; Wang H; Yu X; Zhang Y; Zhao L; Li B; Guo Y
Biochem Biophys Res Commun; 2015 Apr; 459(4):617-22. PubMed ID: 25749344
[TBL] [Abstract][Full Text] [Related]
13. CD20-Mimotope Peptides: A Model to Define the Molecular Basis of Epitope Spreading.
Favoino E; Prete M; Catacchio G; Conteduca G; Perosa F
Int J Mol Sci; 2019 Apr; 20(8):. PubMed ID: 31003532
[TBL] [Abstract][Full Text] [Related]
14. HuMab-7D8, a monoclonal antibody directed against the membrane-proximal small loop epitope of CD20 can effectively eliminate CD20 low expressing tumor cells that resist rituximab-mediated lysis.
van Meerten T; Rozemuller H; Hol S; Moerer P; Zwart M; Hagenbeek A; Mackus WJ; Parren PW; van de Winkel JG; Ebeling SB; Martens AC
Haematologica; 2010 Dec; 95(12):2063-71. PubMed ID: 20851867
[TBL] [Abstract][Full Text] [Related]
15. Crystal structure of chimeric antibody C2H7 Fab in complex with a CD20 peptide.
Du J; Wang H; Zhong C; Peng B; Zhang M; Li B; Hou S; Guo Y; Ding J
Mol Immunol; 2008 May; 45(10):2861-8. PubMed ID: 18346788
[TBL] [Abstract][Full Text] [Related]
16. New anti-CD20 monoclonal antibodies for the treatment of B-cell lymphoid malignancies.
Robak T; Robak E
BioDrugs; 2011 Feb; 25(1):13-25. PubMed ID: 21090841
[TBL] [Abstract][Full Text] [Related]
17. C1q A08 Is a Half-Cryptic Epitope of Anti-C1q A08 Antibodies in Lupus Nephritis and Important for the Activation of Complement Classical Pathway.
Wu WJ; Tan Y; Liu XL; Yu F; Zhao MH
Front Immunol; 2020; 11():848. PubMed ID: 32536911
[TBL] [Abstract][Full Text] [Related]
18. Antibody Distance from the Cell Membrane Regulates Antibody Effector Mechanisms.
Cleary KLS; Chan HTC; James S; Glennie MJ; Cragg MS
J Immunol; 2017 May; 198(10):3999-4011. PubMed ID: 28404636
[TBL] [Abstract][Full Text] [Related]
19. Complement activation determines the therapeutic activity of rituximab in vivo.
Di Gaetano N; Cittera E; Nota R; Vecchi A; Grieco V; Scanziani E; Botto M; Introna M; Golay J
J Immunol; 2003 Aug; 171(3):1581-7. PubMed ID: 12874252
[TBL] [Abstract][Full Text] [Related]
20. Mapping of the C1q binding site on rituxan, a chimeric antibody with a human IgG1 Fc.
Idusogie EE; Presta LG; Gazzano-Santoro H; Totpal K; Wong PY; Ultsch M; Meng YG; Mulkerrin MG
J Immunol; 2000 Apr; 164(8):4178-84. PubMed ID: 10754313
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]